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Abstract
Influenza A viruses are a major cause of morbidity and mortality in the human population, causing epidemics in the winter,
and occasional worldwide pandemics. In addition there are periodic outbreaks in domestic poultry, horses, pigs, dogs, and
cats. Infections of domestic birds can be fatal for the birds and their human contacts. Control in man operates through
vaccines and antivirals, but both have their limitations. In the search for an alternative treatment we have focussed on
defective interfering (DI) influenza A virus. Such a DI virus is superficially indistinguishable from a normal virus but has a
large deletion in one of the eight RNAs that make up the viral genome. Antiviral activity resides in the deleted RNA. We have
cloned one such highly active DI RNA derived from segment 1 (244 DI virus) and shown earlier that intranasal administration
protects mice from lethal disease caused by a number of different influenza A viruses. A more cogent model of human
influenza is the ferret. Here we found that intranasal treatment with a single dose of 2 or 0.2 mg 244 RNA delivered as A/PR/
8/34 virus particles protected ferrets from disease caused by pandemic virus A/California/04/09 (A/Cal; H1N1). Specifically,
244 DI virus significantly reduced fever, weight loss, respiratory symptoms, and infectious load. 244 DI RNA, the active
principle, was amplified in nasal washes following infection with A/Cal, consistent with its amelioration of clinical disease.
Animals that were treated with 244 DI RNA cleared infectious and DI viruses without delay. Despite the attenuation of
infection and disease by DI virus, ferrets formed high levels of A/Cal-specific serum haemagglutination-inhibiting antibodies
and were solidly immune to rechallenge with A/Cal. Together with earlier data from mouse studies, we conclude that 244 DI
virus is a highly effective antiviral with activity potentially against all influenza A subtypes.
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Introduction
Human influenza is a debilitating respiratory disease which
arises from seasonal winter outbreaks and catastrophic world-wide
pandemics [1–3]. Measures to combat influenza include vaccines
[4–6] and antivirals [7–9]. Both have their strengths and
weaknesses. Current vaccines are highly specific and to be effective
have to be closely matched to the prevailing virus and immunity
takes 1–3 weeks to reach maximum efficacy. People whose
immune system is compromised (including the elderly) may not
make a fully protective immune response or their immunity may
wane too quickly to be effective [10,11]. The antivirals oseltamivir
and zanamivir protect against all influenza A and B strains and
can be used prophylactically or therapeutically. Oseltamivir and
zanamivir are administered twice daily, and are most effective
when taken before or soon after infection. However, oseltamivir-
resistant mutants were already wide-spread in seasonal H1N1
virus prior to 2009 [12,13], and are now appearing in the 2009
pandemic virus [14–16]. More counter-measures, especially those
that are broad-spectrum and not subject to virus resistance are
urgently needed.
Our approach is to use defective-interfering (DI) virus [17],
which is produced by nearly all viruses during their replication
process, as an antiviral in vivo. DI viruses are widely known to have
powerful antiviral (interfering) activity in cell culture but, with a
few notable exceptions, there is little indication that this activity
translates into conferring protection from disease in animal models
[18]. One of the first accounts, more than 60 years ago, refers to
what is now known as DI influenza virus [19,20]. A DI influenza
virus is defective as it has a large deletion in the central region of
one of the 8 viral RNA segments that constitute the infectious
genome. This is a DI RNA. Not all defective RNAs are interfering,
hence interference is a particular property of a certain class of
defective RNA. Influenza DI particles are indistinguishable from
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normal infectious particles except in that they contain at least one
genomic segment that has undergone a massive deletion. Any one
of the 8 genomic segments can give rise to a DI RNA, although DI
RNAs arise most frequently from segments 1, 2 or 3. The situation
is made more complex as the position of the central deletion in any
one segment can vary considerably, so giving rise to many different
DI RNA sequences. Natural populations of DI influenza virus can
contain greater than 50 different defective RNA sequences
[21,22], and initially it was impossible to produce a defined DI
virus preparation that could be quality controlled. We solved this
problem by using cloning techniques to isolate single, naturally
occurring DI RNAs of known sequence [22]. One of these DI
RNAs, originating from segment 1 (called 244), was incorporated
by reverse genetics into A/PR/8/34 influenza virus to form the DI
virus 244/PR8. This DI virus is highly effective in protecting
against clinical disease caused by a lethal influenza challenge in a
mouse model [23]. In mice a single intranasal dose administered
before or at the same time as the infectious virus completely
suppresses clinical disease symptoms caused by H1N1, H2N2,
H3N2 or H3N8 viruses also given intranasally. Post-infection
therapy is also effective. 244/PR8 is not toxic and generates no
adverse clinical effects, and the administered preparation is not
infectious. Different strains of mice and elderly mice are well
protected [24–26]. Infection of mice with severe-combined
immunodeficiency (SCID) shows that the adaptive immune
response is not required for protection but is needed to clear
infection [24]. Interferon is made locally in the respiratory tract in
response to DI virus but is not required for protection from
influenza A viruses. However, interferon affords protection from
heterologous respiratory viruses such as influenza B and a
paramyxovirus, pneumonia virus of mice [26,27]. On this basis
DI virus offers a potentially attractive new addition to the armoury
of anti-influenza treatments.
A DI influenza virus is not capable of independent replication as
it contains at least one defective RNA segment. However, when an
infectious virus particle enters a cell which a DI virus has already
invaded, it replicates not only its own full length RNA segments
but also the DI RNA. Little is known of the details of the
mechanism by which an influenza DI virus achieves its antiviral
effects, but it is characteristic of all DI viruses that defective
particles come to predominate over infectious virus in a cell culture
[28]. All influenza DI RNAs retain the common replication and
packaging signals that are located at the termini of each RNA
segment [8,23] suggesting that the DI genome is recognised by and
subverts the viral replication machinery so that DI RNAs are
made in preference to full-length genomic RNAs. In addition there
is probably preferential packing of the DI genome with the cell
producing more non-infectious DI virus than infectious virus
particles [29]. It is envisaged that protection in vivo against
influenza A viruses operates through decreasing the infectious
virus load, while increasing the production of DI RNA and DI
virus. This significantly reduces or obviates clinical disease, and
gives the adaptive immune system time to become activated and
clear the infection. Because the majority of progeny virus (both DI
and infectious virus) is packaged by the proteins of the infecting
virus, a solid adaptive immunity is generated that protects mice
from further infection by the same strain of virus [23,25].
Although we have extensive proof of concept in mice, protection
of ferrets is the accepted pre-clinical acid test for influenza vaccines
and antivirals. Ferrets are highly sensitive to infection by human
influenza viruses [30,31], and mount a disease that closely
resembles that in humans [32–36]. Ferrets have been used in
many aspects of influenza biology including the study of recent
human [37,38] and avian influenza viruses [39–43], airborne
transmission [36,37,44], the evaluation of vaccines [6,14,19],
testing antivirals [45,46], and the interaction with bacteria in the
respiratory tract [47]. We have evaluated the ability of a single
intranasal dose of cloned DI virus (containing as little as 0.2 mg of
antiviral DI RNA) to protect ferrets from the recent 2009
pandemic influenza A virus (A/California/04/09, H1N1). We
report that all clinical signs of disease were significantly reduced
and that animals mounted a solid virus-specific antibody response
and became immune to reinfection with A/California/04/09.
Results
Influenza in ferrets caused by the pandemic influenza
virus A/California/04/09 (H1N1) (A/Cal)
Typically ferrets infected with A/Cal (102 TCID50) show a peak
of virus infectivity in nasal washes on days 2 and 3, which then
declines and is undetectable by day 8. The peak of infectivity is
followed one day later by a fever spike (.40uC) and a significant
but transient weight loss (day 3). There is an increase in the
number of small round cells in nasal washes that commences on
day 2 and peaks on day 3. This declines slowly and is still above
baseline on day 14. The peak of infection is accompanied by
pronounced nasal discharge and sneezing. However, there is no
significant loss of appetite, loss of activity, or diarrhoea (data not
shown).
244 DI virus reduces fever in A/Cal-infected ferrets
Groups of 5 ferrets were infected intranasally with A/Cal (102
TCID50). Animals were treated at the same time with an
intranasal dose of active 244 DI virus containing approximately
2 mg or 0.2 mg of active agent (244 RNA) in 300 or 30 mg
respectively of virus protein or with UV-inactivated 244 DI virus
(300 or 30 mg). Figure 1A shows that the control infected ferrets
treated with either 300 or 30 mg of inactivated 244 DI virus
displayed a fever spike on day 3 post infection (pi) which is a clear
sign of disease. Infected animals treated with active 244 DI virus
had significantly lower temperatures on day 3 compared to the
control group treated with inactivated 244 DI virus. The mean
group temperature rises for infected animals treated with 300 mg
244 DI virus or inactivated 244 DI virus respectively were 0.58uC
and 1.44uC (Student’s t-test p = 0.039). Similarly, ferrets treated
with 30 mg of 244 DI or inactivated 244 DI experienced mean
temperature rises of 0.84uC and 1.34uC (p = 0.016) (Fig. 1B).
Control non-infected animals treated with 300 mg of 244 DI virus
or saline had no fever peak (data not shown).
Temperature changes were also recorded by subcutaneously
implanted transponders. These confirmed a fever peak on day 3 in
infected animals given control inactivated 244 DI virus. Animals
treated with 300 mg of active 244 DI virus had significantly less
fever than animals treated with the same amount of inactivated
244 DI virus (0.16uC increase compared with a 1.2uC increase,
p = 0.025) while animals treated with the lower dose of 30 mg 244
DI virus also had significantly less fever than animals treated with
the same amount of inactivated 244 DI virus (0.02uC for 244 DI
virus and 0.84uC for inactivated 244 DI virus, p = 0.009) (data not
shown).
The data show that active 244 DI virus significantly reduces the
fever response in ferrets infected with A/Cal. The 30 and 300 mg
doses of 244 DI virus gave similar protection.
244 DI virus reduces weight loss in A/Cal-infected ferrets
A/Cal-infected ferrets treated with 300 mg 244 DI virus showed
a smooth increase in weight over the period of observation
(Fig. 2A). In contrast, infected animals treated with inactivated 244
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DI virus showed a pronounced and highly significant weight loss
on day 3, falling to below their initial mean group weight. These
animals then resumed weight gain but from days 3–8 their weights
were significantly lower than the 244 DI virus-treated group, and
from days 9–14 were all still lower than the 244 DI virus-treated
group at the end of the experiment, although not significantly so.
Animals treated with 30 mg 244 DI virus showed a small weight
loss on day 3 but weights were still significantly greater than the
control group treated with an equivalent amount of inactivated
244 DI virus from days 3–14 (Fig. 2B). Ferrets treated with 300 mg
active 244 DI virus (but not infected with A/Cal) gained weight
steadily at a very similar trajectory to those given saline, indicating
that the higher dose of 244 DI virus had no deleterious effect of
weight gain (Fig. 2C).
244 DI virus reduces respiratory disease (sneezing and
nasal discharge) in A/Cal-infected ferrets
Sneezing and nasal discharge are typical clinical signs of
influenza, and ferrets were monitored twice daily for changes in
these parameters. Data for combined sneezing and nasal discharge
observations are shown in Figure 3, where the reductions effected
by 244 DI virus were highly significant (one tailed Mann-Whitney
U test, p = 0.006). 300 mg 244 DI virus reduced sneezing and nasal
discharge calculated in a variety of combinations, with all being
statistically significant (p#0.05). 30 mg 244 DI virus had lower
efficacy, but significantly reduced nasal discharge (Table S1).
244 DI reduces A/Cal infectivity in ferret nasal washes
Nasal washes were taken daily from ferrets and assayed for
infectious A/Cal and for 244 DI RNA (see next section). Figure 4A
shows that low amounts of infectivity appeared in control ferrets
treated with inactivated 244 DI virus in day 1, peaked on day 2,
and then began to decline from day 3. In animals treated with
Figure 1. Change in rectal temperatures in ferrets infected with A/California/04/09 (H1N1) and treated with 244 DI virus
simultaneously on day 0. Ferrets were treated with A/Cal+300 mg 244 DI virus (X); A/Cal+30 mg 244 DI virus (&); A/Cal+300 mg inactivated 244 DI
virus (m); A/Cal+30 mg inactivated 244 DI virus (x). In (a) the mean changes in temperatures of each group (n = 5) are expressed as the difference to
the group average temperature on day 0. Animals were anaesthetised and rectal temperatures taken prior to any other procedure. The arrow
denoted the fever spike on day 3 post infection/treatment. In (b) the statistical significance of temperature change differences on day 3 after
infection/treatment with 300 mg (left-hand panel) or 30 mg (right-hand panel) 244 DI virus or inactivated (i) 244 DI virus were determined using a one
tailed unpaired t-test. The mean temperature change seen in ferrets treated with 300 mg 244 DI was 0.58uC (SD 60.19uC) and in those treated with
300 mg inactivated 244 DI virus was 1.44uC (SD 60.74uC). The mean temperature change seen in ferrets treated with 30 mg 244 DI was 0.84uC (SD
60.30uC) and in those treated with 30 mg inactivated 244 DI virus was 1.34uC (SD 60.30uC).
doi:10.1371/journal.pone.0049394.g001
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300 mg 244 DI virus infectious virus was also first detected on day
1, but peaked over days 3–5, being both delayed and reduced. The
reduction of infectivity by 244 DI virus on day 2 (764-fold) was
highly significant (p = 0.008); the reduction on day 3 was 17-fold
and was also significant (p = 0.095), both using a two-tailed Mann-
Whitney U test (Fig. 4B, 4C). Infectivity levels in DI virus-treated
animals were maintained until day 5, and were undetectable on
day 8, showing that 244 DI virus did not prolong infection (Table
S2). The dynamics of infectious virus in animals treated with a 10-
fold lower dose of 244 DI virus (30 mg) were very similar to those
observed with the higher DI virus dose.
244 DI RNA is hugely amplified in nasal washes of ferrets
infected with A/Cal
244 RNA is the antiviral active principle responsible for
protection from influenza A virus infection [23]. To determine
how this interaction proceeded in the ferret, nasal washes were
assayed for the presence of DI virus-specific 244 RNA by
quantitative RT-PCR. Figure 5 shows that 244 DI RNA was
below detectable levels in animals treated with 244 DI virus at 1
day after treatment. However, by day 2, 244 DI virus RNA levels
had increased by $1000 to 10,000-fold, showing that it was being
replicated by A/Cal. Amounts of DI RNA in the individual ferrets
within a group were highly reproducible (Figure S1). The small
amount of 244 DI RNA in the groups given inactivated DI virus
and A/Cal is the result of incomplete destruction of DI RNA.
Levels of DI RNA declined and were undetectable by day 10 after
infection. There was no discernible difference in the 244 DI RNA
dynamics in ferrets treated with 300 mg or 30 mg of active 244 DI
virus. These data demonstrate for the first time in ferrets the ability
of the 244 DI RNA to be amplified by the agent that it is acting
against – in this case A/Cal influenza virus. This observation is
fully consistent with data arising from the mouse model [23,24].
Other clinical parameters
Ferrets were also monitored over 21 days post infection for
diarrhoea (1 instance reported in each of infected 2 ferrets), change
(loss) of appetite (none recorded), and changes in activity/
behaviour (7 instances recorded in 4 different groups). None was
considered significant. The number of cells in nasal washes
increased by approximately 50-fold in all A/Cal-infected animals
compared with the saline-treated group, although 244 DI virus on
its own did not stimulate the cell content of nasal washes, and did
not differ from the group treated with saline (data not shown). It
seems therefore that the increase in cells in nasal washes is a
response to infectious influenza virus. In addition serum HI titres
Figure 2. Changes in weight of ferrets over the course of
infection with A/Cal. Shown is the mean group body weight changes
in A/Cal influenza virus-infected ferrets treated with (a) 300 mg 244 DI
virus (&) or inactivated 244 DI virus (m), (b) 30 mg 244 DI virus (&) or
inactivated 244 DI virus (m). (c) Shows the weight changes in ferrets
inoculated with saline (#) or treated with 300 mg of active 244 DI virus
(N). Data are expressed as a percentage change compared to the group
average weight at day 0. The statistical significance of body weight
changes on any one day was determined by a one tailed unpaired t-test
and is indicated by an asterisk (p#0.05).
doi:10.1371/journal.pone.0049394.g002
Figure 3. Analysis of combined sneezing and nasal discharge
data in A/Cal infected ferrets treated with 300 mg of active 244
DI virus (&) or 300 mg of inactivated (i) 244 DI virus (m). The
horizontal line indicates the mean: 244 DI virus mean was 10.45%;
inactivated 244 DI virus mean was 22.73%. The values are the
occurrence of sneezing and nasal discharge events in each group over
the 14 days of observation. The scores were assigned 10% for each
individual event such that all 5 ferrets were positive for both sneezing
and nasal discharge would be scored as 100%; a.m. and p.m.
assessments are separate. Zero was only scored when the other group
was positive. The p value was determined using a one tailed Mann-
Whitney U test.
doi:10.1371/journal.pone.0049394.g003
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specific to A/California/04/09 (H1N1) taken at 14 days after
infection were unaffected by the treatment with 244 DI virus, with
titres in all A/Cal-infected groups rising from ,1/40 to .1/8000
(data not shown).
Ferrets protected from A/Cal with DI virus are immune to
reinfection with A/Cal
We have previously shown that mice protected by 244 DI virus
were solidly immune to rechallenge with the same virus [23]. This
allayed concerns that, following treatment with 244 DI virus, the
challenge infection had been attenuated and might result in a
weaker adaptive immune response. To determine the situation in
ferrets, the groups initially receiving A/Cal+300 mg active 244 DI
virus, A/Cal+300 mg inactivated 244 DI virus, and a saline
inoculum were challenged with A/Cal at 21 days after the initial
A/Cal infection. A dose of (106 TCID50) was chosen as high doses
of influenza virus overcome the protection mediated by DI virus in
mice (unpublished data). Thus any protection observed could be
attributed to adaptive immunity. Naı¨ve animals showed a peak
mean rise in rectal temperature (0.96uC) on day 2, while the
temperature of other previously infected groups increased by
#0.2uC. This difference was statistically significant (p#0.03).
These animals were protected regardless of treatment with DI
virus (Figure S2). Temperature recording by transponder chip
gave a similar result with a temperature spike only in naı¨ve animals
(of 0.66uC compared with #0.18uC for the other groups) (data not
shown). Only naı¨ve animals experienced significant weight loss
following challenge, also on day 2. In particular, A/Cal-infected
ferrets that had previously been treated with 244 DI virus were
highly significantly better at gaining weight over days 2–7 than
those treated with inactivated 244 DI virus (Figure S3). Table S3
summarizes particulars of sneezing, nasal discharge, activity loss
Figure 4. Summary of A/Cal infectivity in nasal washes. Panel (a) shows ferrets infected with A/Cal on day 0 and treated with 300 mg 244 DI
virus (&) or infected and treated with 300 mg inactivated 244 DI virus (m); another group was not infected but treated with 300 mg of active 244 DI
virus (N). A standard preparation of A/Cal virus was used to normalise titrations carried out on different days. These varied by less than 4-fold. The
dotted line is the limit of sensitivity of the assay (1.92 log10 FFU/ml). Significant reduction in infectivity (by a two-tailed Mann-Whitney U test) in ferrets
treated with 244 DI virus is denoted by **. Panels (b) and (c) show details of the statistical analysis on day 2 and 3, respectively.
doi:10.1371/journal.pone.0049394.g004
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and appetite loss in individual ferrets. Naı¨ve animals were positive
for all clinical signs on at least 2 observation days following
challenge. Most, if not all, animals displayed one or more clinical
sign during the observation periods. In contrast, groups that had
previously been infected with A/Cal showed only very occasional
signs of sneezing, and no sign of disease. The reduction in clinical
signs in non-naı¨ve animals compared to the naı¨ve control was
highly significant (p,0.0001) (Fig. 6). In conclusion, ferrets that
had been protected from influenza by treatment with 244 DI virus
were able to mount an immune response that protected them from
subsequent challenge with the same virus in the same way that was
seen with control infected animals. This finding is entirely
consistent with the high serum HI antibody titres found in all
A/Cal-infected ferret groups, as reported above.
Discussion
The ferret model of influenza is viewed as the closest to the
human disease, and is widely used to evaluate vaccines and other
anti-influenza measures. In this study we infected ferrets with an
isolate from the latest influenza pandemic (A/California/04/
2009). The possibility that DI virus might have a moderating effect
on influenza has long intrigued virologists but the only data
relevant to the ferret model is our preliminary study in which
animals were protected using an intranasal dose of a DI virus
preparation which contained an unspecified number of DI RNAs
[48]. Here we have investigated the protection afforded by a fully
defined, cloned DI RNA delivered in an influenza virus particle.
The delivery vehicle was carefully selected to recognise both the
a2,6 and a2,3 sialic acid receptors recognised by influenza A
viruses [49], so that 244 DI RNA is delivered to cells that can
potentially be infected by an incoming influenza virus. This is
important as when we treated ferrets with 244 DI RNA in a strain
of PR8 that recognises predominantly a2,3 sialic acid receptors
there was no amelioration of infection by infectious virus that
recognised predominantly a2,6 sialic acid receptors. In that study
the DI RNA was eventually amplified by the challenge virus A/
Sydney/5/97 (H3N2), but presumably too late to be of any clinical
benefit (unpublished data).
The data above (summarized in Table 1) show clearly that both
doses of 244 DI RNA (300 or 30 mg of DI virus containing 2 or
0.2 mg of 244 DI RNA, respectively) significantly ameliorated
clinical disease caused by A/Cal infection. The higher dose
resulted in a reduction in every clinical parameter tested (fever,
weight loss, sneezing and nasal discharge, and infectious load),
which was concomitant with the enhancement of 244 RNA in
nasal washes. DI RNA was undetectable by a sensitive quantitative
RT-PCR at 1 day post treatment, but was amplified on infection,
and appeared in nasal washes at the same time as infectious virus.
The overall reduction in symptoms was similar to that observed
with oseltamivir treatment of ferrets infected with the same virus,
where the animals were treated within 2 hours of infection and
then twice daily for 5 days [50]. The present study used only a
single very low dose of DI RNA (2 or 0.2 mg), whereas most
antivirals are used in milligram amounts with multiple doses. It is
also relevant to the success of the treatment that infectious A/Cal
was not detected beyond 8 days post infection, and that the DI
RNA was not detected beyond 10 days by quantitative RT-PCR:
the presence of amplified active DI RNA made no difference to
the dynamics of clearance. 244 DI RNA amplified by A/Cal
would be expected to be packaged as a DI virus particle with
proteins, including the surface haemagglutinin and neuraminidase,
synthesised by A/Cal. Further, it is likely that this DI 244/Cal
virus transmitted its 244 DI RNA to other cells in the respiratory
tract where it protected them from infection. In principle, such a
DI 244/Cal virus may also be transmitted in airborne droplets/
aerosols of nasal secretions, along with infectious virus, to other
Figure 5. 244 DI virus (244) RNA is amplified in nasal washes by
A/Cal. Ferrets were infected with A/Cal on day 0 and treated with 244
DI virus or inactivated 244 DI virus. Levels of 244 DI RNA were
determined by quantitative RT-PCR. Mean 244 RNA copy numbers for
each ferret group (n = 5) are plotted. Panel (a) shows ferrets that were
infected with A/Cal influenza virus and treated with 300 mg 244 DI virus
(&), or 30 mg 244 DI virus (m), or 300 mg (i) inactivated 244 DI virus (.),
or 30 mg (i) inactivated 244 DI virus (X). Panel (b) shows non-infected
ferrets that were given 300 mg 244 DI virus (%), or diluent (n). The
dotted line shows the limit of detection. Figure S1 gives details for
individual animals.
doi:10.1371/journal.pone.0049394.g005
Figure 6. Statistical analysis of summed clinical signs for each
day in ferrets re-challenged with A/Cal. The group that previously
experienced A/Cal+300 ug 244 DI virus (&) is compared with the group
that previously experienced only saline (m). The p value was
determined using a one tailed Mann-Whitney U test.
doi:10.1371/journal.pone.0049394.g006
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individuals. It will be of interest to determine how DI virus might
alter the dynamics of influenza transmission and infection.
One important proviso of treating a virus infection is that the
immune response is not so weakened that the cognate adaptive
immune response is compromised. Accordingly, we tested
immunity measuring the amount of virus-specific serum antibody
by HI and by challenging animals with a second dose of A/Cal.
Despite the amelioration of the A/Cal-mediated clinical disease by
treatment with DI virus we found that there were similar levels of
HI antibody in all infected groups. Animals re-challenged with A/
Cal at 21 days were solidly protected from disease. This protection
was most likely mediated by serum HI antibody, which is known to
be protective, and other adaptive immune responses rather than
by residual DI RNA, as DI RNA could not be detected in nasal
wash or tissues (data not shown) at 14 days after the first infection.
Innate immune responses stimulated by the original infection are
probably not a factor in protection at the time of rechallenge, as
most of these responses which rose rapidly in ferrets in concert
with the symptoms of influenza, had declined significantly by 6
days post infection [51].
The antiviral activity resulting from intranasal administration of
244 DI virus in ferrets has a number of unique features. Protection
requires only a single dose, a very small amount (0.2 mg) of DI 244
RNA, and delivery to cells by 104 HAU of an influenza A virus
(approximately 30 mg) that recognises a2,6 and a2,3 sialic acid
receptors [49]. DI RNA is amplified only if cells are infected by an
influenza A virus, otherwise the DI RNA degrades. In mice
protection mediated by a single critical dose of 244 DI virus is lost
1–2 weeks after treatment (unpublished data). Treatment with DI
RNA does not affect clearance of infectious influenza virus, and
the DI RNA itself rapidly disappears from nasal washes. In
addition, in mice DI virus stimulates sufficient interferon type I to
protect against respiratory disease caused by non-influenza virus
although this is not needed for protection from influenza A viruses
[26,27]. The development of resistance to 244 DI virus has not
been detected. For this to occur, the polymerase, which is encoded
by infectious virus and is used by all 8 full-length segments, would
have to acquire amino acid changes such that it no longer
recognised the DI RNA while at the same time acquiring
compensating mutations in all 8 full-length segments simulta-
neously (unpublished data). Given a mutation rate of 1025, the
chance of this occurring is approximately 10240, hence this is
unlikely to arise. Finally, A/Cal-infected animals that are
protected by DI RNA mount a normal HI antibody response
and are solidly immune to rechallenge with the same virus. The
treatment demonstrated above could be considered directly
relevant to treatment of humans who had just been or were about
to be exposed to infection. We need in due course to determine the
limitations of treatment or after before infection, and if these
mirror the data we have already produced in mice [23]. In
summary, data here underline the strong antiviral capacity of 244
DI virus and demonstrate how it could be used as a novel antiviral
in a clinical context.
Materials and Methods
Ethics statement
The experimental animal work described here has been
scrutinised and approved by the Ethical Review Committee of
the Health Protection Agency (Porton), as required by the UK
Home Office Animals (Scientific Procedures) Act, 1986. All animal
work was conducted according to UK Home Office legislation for
animal experimentation. The premises in which the work was
conducted are approved under Home Office Certificate of
Designation PCD70/1707.
Production of cloned 244 DI virus by reverse genetics
244 DI RNA was originally generated spontaneously from
segment 1 during the transfection of 293T cells with plasmids
required to make infectious influenza A/PR/8/34 [52]. Its
sequence has been published [23,52]. The original 244/PR8 DI
virus protected mice from lethal influenza but ferrets were not
protected effectively (unpublished data). This related to the
receptor specificity of the HA as a2,3-linked sialyl receptor
sequences are predominant in the mouse respiratory system, and
a2,6-linked sialyl receptor sequences predominant in the ferret
respiratory system [53–55]. Thus to make the DI virus for the
current study we cloned and used the HA and NA proteins from a
different substrain of PR8 (A/PR8(Warwick), which binds to both
a2,6- and a2,3-linked sialyl receptors [49]. An uncloned DI A/
PR8(Warwick) had earlier successfully protected ferrets from an
H3N2 virus [48]. The new recombinant virus bound as expected
to a2,6- and a2,3-linked sialic acids in a surface plasmon
resonance assay (data not shown). Plasmids were transfected into
293T cells and, after 24 h, these were trypsinized, mixed with
MDCK cells and re-plated. Resulting virus was passaged once in
embryonated chicken’s eggs, and the resulting mixture of 244/
PR8 DI virus and infectious helper PR8 virus was purified away
from extraneous contaminating material by differential centrifu-
gation through sucrose. Stocks were resuspended in PBS
containing 0.1% w/v bovine serum albumin, standardized by
haemagglutination titration, and stored in liquid nitrogen.
Protection activity in mice was comparable to that shown earlier
[23]. DI virus was UV-irradiated to remove helper virus infectivity
with a short burst (50 seconds) of UV irradiation at 253.7 nm
(0.64 mW/cm2) (‘active DI virus’ [23]). Longer UV irradiation
(8 minutes) inactivates protecting activity for mice although it does
not destroy all DI RNA (‘inactivated DI virus’). It does not affect
haemagglutinin or neuraminidase activities, and so controls for
any immune system-stimulating or receptor-blocking effects of 244
DI virus particles.
Challenge virus preparation
Pandemic 2009 influenza H1N1 A/California/04/2009 (A/
Cal; from CDC Atlanta, GA) was propagated in Madin-Darby
Table 1. Summary of 244 DI virus-mediated protection of
ferrets from influenza caused by A/Cal.
Benefit of treatment 244 DI virus
300 mg 30 mg
Reduction in fever by rectal temperature recording Yes* Yes
Reduction in fever by chip temperature recording Yes Yes
Reduction in loss of body mass Yes Yes
Reduction in sneezing Yes No
Reduction in nasal discharge Yes Yes
Reduction in combined sneezing & nasal discharge Yes No
Reduction of A/Cal infectivity in nasal washes Yes Yes
Increase in 244 DI RNA in nasal washes Yes Yes
Immunity to rechallenge with A/Cal Yes ND
*Statistically significant at $95% confidence limits; data presented
elsewhere in this report.
ND, not done.
doi:10.1371/journal.pone.0049394.t001
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canine kidney (MDCK) cells (Health Protection Agency Culture
Collection) and titrated by limiting dilution in the same cell type to
give a 50% tissue culture infectious dose (TCID50).
Ferret studies
All ferret experimental work was conducted according to UK
Home Office legislation for animal experimentation and was
approved by the local ethical committee. Thirty male ferrets
(Mustela putorius furo), 3–4 months of age, were obtained from
Highgate Farm, UK. All ferrets were confirmed to be seronegative
for antibodies to H1N1 influenza as determined by haemagglu-
tination-inhibition. Ferrets were separated into 6 groups, each
comprising 5 animals, and a unique identifier body temperature
transponder (idENTICHIP, Bio-Thermo) was inserted subcuta-
neously into the scruff of each ferret. Ferrets were sedated by
intramuscular injection of ketamine (17.9 mg/kg) and xylazine
(3.6 mg/kg) then each ferret was intranasally inoculated with
500 ml (250 ml per nare) of challenge solution. Groups of ferrets
(n = 5) were infected intranasally with 100 TCID50 of the
pandemic 2009 influenza virus A/California/04/09 (H1N1) (A/
Cal). The DI virus test groups were treated intranasally with a
mixture of A/Cal and active 244 DI virus containing approxi-
mately 2 mg 244 RNA in 300 of virus protein, or with A/Cal and
0.2 mg 244 RNA in 30 mg of virus protein. Control groups
received virus and UV-inactivated 244 DI virus equivalent to the
2 mg RNA dose, virus and UV-inactivated 244 DI virus equivalent
to the 0.2 mg RNA dose, or saline. Each inoculum was prepared
on the day of challenge and the titre of the virus was subsequently
reconfirmed in MDCK cells.
The rectal temperatures of all ferrets were measured daily.
Ferrets were monitored twice-daily post-challenge throughout the
course of the study for clinical signs indicative of influenza
infection (lack of activity, sneezing, nasal discharge, lack of
appetite, weight loss and pyrexia). Each animal was monitored for
up to 5 minutes by trained animal technicians. Staff were aware of
which animals were infected and any treatment received. Clinical
signs were scored using a simple matrix depending on severity.
Loss of activity was scored; 0 for normal activity levels, 1 for
reduced activity and 2 if inactive. Nasal discharge was scored 0 if
no nasal discharge was present and 1 if nasal discharge was
present. Sneezing was scored; 0 if no sneezing and 1 if ferrets were
sneezing. Loss of appetite was scored; 0 for no appetite loss and 1
for loss of appetite. Nasal washes were collected from each ferret
following sedation (as above) at days 1–6 and then at days 8, 10 12
and 14 post-challenge. For each nasal wash, 2 ml of PBS were
instilled by small multiple volumes into each nasal cavity with
expectorate collected into a beaker.
At 14 days post-challenge, ferrets in groups 2, 4 and 5 were
sacrificed. Monitoring of ferrets in groups 1, 3 and 6 continued
twice daily for days 15–20 post-challenge. At day 21 post-
challenge ferrets were sedated as before and inoculated intrana-
sally with 106 TCID50 A/Cal in a 500 ml inoculum. Ferrets were
monitored for a further seven days twice daily for clinical signs of
influenza infection. At 28 days post the first challenge all ferrets in
groups 1, 3, 5 and 7 were sacrificed, and blood and tissue samples
taken as before.
PCR assays
RNA was extracted from nasal washes with QIAamp mini RNA
kit (Qiagen) and quantitative real time PCR performed to
quantitate virion-sense RNA using an ABI prism 7000 [24]. We
used the primers and probe: 244 1F (59 CTCTTTGCCCA-
GAATGAGGAAT 39), 244 1R (59 CATAATCAAGAAGTACA-
CATCAGGAAGAC 39) and probe (59 FAM-
CCCTCAGTCTTCTCC 39). Primers were synthesized by
Invitrogen, and the probes by ABI. Reverse transcriptase reactions
(10 ml) were performed using 6 ml extracted RNA, RevertAid
reverse transcriptase and random hexamer (Fermentas) were used
according to the manufacturer’s instructions. cDNA (1 ml) was
used in 20 ml of PCR reaction. A virion-sense 244 RNA standard
was made by subcloning PCR products of full length 244 RNA in
pGEMT-easy vector (Promega). RNA was transcribed using the
T7 RNA polymerase (MEGAscript, Ambion), the mix digested
with DNase I, and RNA purified by electro-elution. After ethanol
precipitation, RNA was resuspended into RNase-free water and
quantitated using a Nanodrop 1000 (Thermoscientific, Wilming-
ton, DE). Standard curves were generated by performing 10-fold
serial dilutions of known RNA copy numbers with each dilution
assayed in duplicate. The reaction was conducted at 50uC for
2 min, 95uC for 10 min, then 40 cycles of 94uC for 15 sec
followed by 60uC for 1 min.
Infectivity assay
Nasal washes from each ferret were titrated for A/Cal infectivity
in a focus-forming assay using MDCK cells in 96-well plates in
triplicate. After infection cells were incubated at 33uC for
18 hours, fixed overnight at 4uC with 1:1 methanol: acetone,
and blocked with 5% w/v milk powder in PBS. Virus-positive cells
were detected using a mouse monoclonal antibody (9G8, Abcam)
that recognises the NP protein of influenza A viruses, and a goat
anti-mouse IgG-alkaline phosphatase conjugate (Sigma), both in
buffered saline containing 0.1% v/v Tween, and finally incubated
with an alkaline phosphatase substrate (NBT/BCIP in TMN
buffer; Sigma). At least 50 stained cells (foci) at an appropriate
dilution were counted in each of three wells and averaged to give a
titre in focus-forming units (FFU) per ferret. Assays carried out on
different days were normalized to a standard A/Cal virus
preparation. Variation in the standard was less than 4-fold.
Haemagglutination-inhibition (HI) assay
Before assay, sera were treated with receptor destroying enzyme
(RDE II (SEIKEN), Cosmos Biological) overnight at 37uC to
remove non-specific inhibitors of haemagglutination and then
incubated at 56uC for 30 min to destroy the enzyme. Serial 2-fold
dilutions of serum were incubated with 4 HAU of A/Cal for
1 hour at ambient temperature before adding chicken red blood
cells (VLA, Weybridge). The HI titre is the dilution of serum that
causes 50% inhibition of agglutination, and is interpolated
between full agglutination and no agglutination [56].
Supporting Information
Figure S1 244 DI virus (244) RNA in nasal washes.
Ferrets were infected with A/Cal on day 0 and treated with 244
DI virus or inactivated 244 DI virus as indicated. Levels of 244 DI
RNA were determined by quantitative RT-PCR. Each point
represents an individual animal. The horizontal line is the
geometric mean for each day, and the dotted line shows the limit
of detection.
(TIF)
Figure S2 Rectal temperatures in ferrets that were
rechallenged with A/Cal 21 days after initial infection.
Prior to challenge with A/Cal ferrets were treated with
A/Cal+300 mg 244 DI virus (&); A/Cal+300 mg inactivated 244
DI virus (m); saline only, and was being infected for the first time
(l). Animals were anaesthetised and rectal temperatures taken prior
to any other procedure. The mean changes in temperatures of
each group (n = 5) are expressed relative to the average
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temperature of the group immediately prior to the challenge
infection on day 0. The fever peak of the virus control occurred on
day 2 and differed significantly by a one tailed unpaired t-test from
the DI virus-treated group (*, p#0.03).
(TIF)
Figure S3 Weight changes in ferret groups rechallenged
with A/California/04/09 (H1N1) 21 days after initial
infection (day 0 on the graph). For other information see
Figure S2. Mean changes in weight of each group (n = 5) are
compared with a baseline established before infection. Animals were
anaesthetised and rectal temperatures taken prior to any other
procedure. Weights of the group originally treated with DI virus
were significantly different by a one tailed unpaired t-test from the
group treated with inactivated DI virus: *, p#0.01; **, p#0.0009.
(TIF)
Table S1 Summary of the reduction of respiratory
disease (sneezing and nasal discharge) in infected ferrets
treated with 244 DI virus or inactivated 244 DI virus.
(DOCX)
Table S2 Summary of nasal wash infectivity and 244 DI
RNA for ferrets infected with A/Cal and treated with
inactivated or active 244 DI virus.
(DOCX)
Table S3 Summary of clinical observations in the 7 days
following rechallenge of ferrets with A/Cal at 21 days
after they were first inoculated. The accumulated number of
single positive events recorded is shown for each group. There
were 14 observation periods and 5 ferrets per group, thus there
was a total of 70 ferret observations.
(DOCX)
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